Risk of Serious Infection With Biologic and Systemic Treatment of Psoriasis-Reference-Cited by-同舟云学术

Risk of Serious Infection With Biologic and Systemic Treatment of Psoriasis

Published:2015-09-01 Issue:9 Volume:151 Page:961
ISSN:2168-6068
Container-title:JAMA Dermatology
language:en
Short-container-title:JAMA Dermatol

Author:

Kalb Robert E.¹,Fiorentino David F.²,Lebwohl Mark G.³,Toole John⁴,Poulin Yves⁵,Cohen Arnon D.⁶,Goyal Kavitha⁷,Fakharzadeh Steven⁷,Calabro Stephen⁷,Chevrier Marc⁸,Langholff Wayne⁸,You Yin⁸,Leonardi Craig L.⁹

Affiliation:

1. Department of Dermatology, School of Medicine and Biological Sciences, State University of New York at Buffalo

2. Department of Dermatology, Stanford University School of Medicine, Stanford, California

3. Department of Dermatology, Mount Sinai Medical Center, New York, New York

4. Dermadvances Research, University of Manitoba, Winnipeg, Canada

5. Laval University and Centre de Dermatologique du Quebec Metropolitain, Quebec City, Quebec, Canada

6. Siaal Research Center for Family Medicine and Primary Care, Ben-Gurion University of the Negev, Beer-Sheva, Israel

7. Janssen Scientific Affairs, LLC, Horsham, Pennsylvania

8. Janssen Research & Development, LLC, Horsham and Spring House, Pennsylvania

9. Department of Dermatology, Saint Louis University School of Medicine, St Louis, Missouri

Publisher

American Medical Association (AMA)

Subject

Dermatology

Cited by 316 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advancements in the Transdermal Drug Delivery Systems Utilizing Microemulsion-based Gels;Current Pharmaceutical Design;2024-10

2. A randomized, double-blind, phase III study assessing clinical similarity of SB17 (proposed ustekinumab biosimilar) to reference ustekinumab in subjects with moderate-to-severe plaque psoriasis;Journal of the American Academy of Dermatology;2024-09

3. Quality of reporting and concordance between sources of adverse events in the treatment of moderate-to-severe psoriasis: a cross-sectional study of RCTs from a Cochrane systematic review;Journal of Clinical Epidemiology;2024-09

4. Real‐world safety and efficacy of biologics in elderly patients with psoriasis: A multicenter observational study;The Journal of Dermatology;2024-07-19

5. Biologics Versus JAK Inhibitors. Part II: Risk of Infections. A Narrative Review;Dermatology and Therapy;2024-07-16